L'intérêt à découvert pour Centene donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Centene. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Centene (NYSE:CNC) Stock, Rapport sur les intérêts à découvert

Centene

Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of December 2024, mostly in Medicaid (about 60% of membership), the individual exchanges (about 20%), and Medicare (about 5%). The company also has a military contract and provides Medicare Part D pharmaceutical plans.

Centene Corp

Canna Corp

CHINA NUCLEAR ENERGY TECH by CHINA NUCLEAR ENERGY TECHNOLOGY CORP LTD.

Coincheck Group NV

CANCER CAPITAL CORP by Cancer Capital Corp.

Cancer Capital Corp

CONNECTED MEDIA TECHS INC by Connected Media Technologies, Inc.

Connected Media Technologies Inc

CHUN CAN CAPITAL GROUP by Chun Can Capital Group

Chun Can Capital Group

Core Nickel Corp

CONDUIT CAPITAL LTD ORD by Conduit Capital Ltd.

ETF Series Solutions Range Cancer Therapeutics ETF

CHINA CASTSON 81 FINCE by CHINA CASTSON 81 FINANCE CO.

China Teletech Holding Inc

Cluster Group Holdings Ltd Co

<a href="https://www.bloomberg.com/news/articles/2025-06-05/medicare-surfaces-as-target-for-cuts-to-pay-for-trump-tax-bill?srnd=phx-politics">https://www.bloomberg.com/news/articles/2025-06-05/medicare-surfaces-as-target-for-cuts-to-pay-for-trump-tax-bill?srnd=phx-politics</a>

News

General

CLOV

EHTH

ELEV

GOCO

'Medicare Surfaces as Target for Cuts to Pay for Trump Tax Bill'- Bloomberg

<a href="https://www.bloomberg.com/news/articles/2025-06-05/medicare-surfaces-as-target-for-cuts-to-pay-for-trump-tax-bill?srnd=phx-politics&amp;embedded-checkout=true" title="https://www.bloomberg.com/news/articles/2025-06-05/medicare-surfaces-as-target-for-cuts-to-pay-for-trump-tax-bill?srnd=phx-politics&amp;embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-06-05/medicare-surfaces-as-target-for-cuts-to-pay-for-trump-tax-bill?srnd=phx-politics&amp;embedded-checkout=true</a>

'Medicare Surfaces as Target for Cuts to Pay for Trump Tax Bill' -Bloomberg

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Goldman Sachs analyst Jordan Alliger downgraded the rating for Union Pacific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>) from Buy to Neutral and maintained the price target of $263. Union Pacific shares closed at $221.66 on Friday. <a href="https://www.benzinga.com/quote/UNP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James analyst Frank Louthan downgraded the rating for Rackspace Technology, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXT#NASDAQ">RXT</a>) from Outperform to Market Perform. Rackspace Technology shares closed at $1.14 on Friday. <a href="https://www.benzinga.com/quote/RXT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Andrew Mok downgraded Centene Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) from Overweight to Equal-Weight and slashed the price target from $84 to $65. Centene shares closed at $56.44 on Friday. <a href="https://www.benzinga.com/quote/CNC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>eedham analyst Ami Fadia downgraded the rating for Blueprint Medicines Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) from Buy to Hold and maintained the price target of $130. Blueprint Medicines shares closed at $101.35 on Friday. <a href="https://www.benzinga.com/quote/BPMC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Ladenburg Thalmann analyst Paul Fremont downgraded NorthWestern Energy Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWE#NASDAQ">NWE</a>) from Buy to Neutral and cut the price target from $57.5 to $56. NorthWestern Energy shares closed at $55.33 on Friday. <a href="https://www.benzinga.com/quote/NWE/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying UNP stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="609" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02092148/image-10-1024x609.png" alt="" class="wp-image-935215" style="width:642px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02092148/image-10-1024x609.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02092148/image-10-300x179.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02092148/image-10-768x457.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02092148/image-10.png 1121w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/markets/large-cap/25/06/45719208/cramer-shouldve-told-investors-to-pull-the-trigger-on-trade-desk-cant-believe-how-low-gentex-has-fallen">Cramer: Should&#8217;ve Told Investors To &#8216;Pull The Trigger&#8217; On Trade Desk, Can&#8217;t Believe &#8216;How Low&#8217; Gentex Has Fallen</a> </li>
</ul>
Photo via Shutterstock

Downgrades

Markets

Analyst Ratings

Trading Ideas

BPMC

This Union Pacific Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $68.6, a high estimate of $84.00, and a low estimate of $61.00. A decline of 6.03% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1748869261_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive Centene is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$65.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>David Windley</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$61.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$84.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Michael Ha</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$69.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>David Windley</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$64.00</td>
<td>$53.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Centene. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Centene compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Centene's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Centene's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CNC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Centene analyst ratings.</a>
<h2>Discovering Centene: A Closer Look</h2>
Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of December 2024, mostly in Medicaid (about 60% of membership), the individual exchanges (about 20%), and Medicare (about 5%). The company also has a military contract and provides Medicare Part D pharmaceutical plans.
<h3>Unraveling the Financial Story of Centene</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Centene's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 15.38%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Centene's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 2.81%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Centene's ROE excels beyond industry benchmarks, reaching 4.83%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Centene's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.55% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Centene's debt-to-equity ratio is below the industry average at 0.66, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Centene: 5 Analysts Share Their Views

Barclays analyst Andrew Mok downgrades Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) from Overweight to Equal-Weight and lowers the price target from $84 to $65.

Price Target

Barclays Downgrades Centene to Equal-Weight, Lowers Price Target to $65

Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) has outperformed the market over the past 15 years by 5.09% on an annualized basis producing an average annual return of 16.93%. Currently, Centene has a market capitalization of $28.55 billion. 
Buying $100 In CNC: If an investor had bought $100 of CNC stock 15 years ago, it would be worth $1,033.15 today based on a price of $57.38 for CNC at the time of writing.
<h3>Centene's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748386862_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today

Sen. Elizabeth Warren (D-Mass.) unleashed sharp criticism of President Donald Trump&#8216;s $3.8 trillion tax package after the House narrowly <a href="https://www.benzinga.com/news/25/05/45581297/trumps-big-beautiful-3-8-trillion-bill-squeaks-through-house-expert-says-it-will-boost-the-economy-in-the-short-term-but-worsen-deficits">approved the legislation 215-214 on Thursday</a>, accusing billionaires Jeff Bezos and Elon Musk of celebrating while millions face healthcare cuts.
What Happened: &#8220;Elon Musk and Jeff Bezos are popping champagne because House Republicans just passed Trump&#8217;s &#8216;big, beautiful bill,'&#8221; Warren wrote on X. &#8220;This bill is a big tax handout for billionaires, paid for by ripping health insurance from 14 million people.&#8221;
The legislation now advances to the <a href="https://www.benzinga.com/news/25/05/45581297/trumps-big-beautiful-3-8-trillion-bill-squeaks-through-house-expert-says-it-will-boost-the-economy-in-the-short-term-but-worsen-deficits">Senate before the July 4 recess</a>. Bond markets reacted sharply to the passage, with 30-year Treasury yields spiking to 5.15% — the highest level since October 2023 — as investors demand higher compensation for increased fiscal risk.
Warren warned the bill represents &#8220;the greatest transfer of wealth from the poor to the billionaires in one bill in all of U.S. history.&#8221; 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">BREAKING: Elon Musk and Jeff Bezos are popping champagne because House Republicans JUST passed Trump's "big, beautiful bill." This bill is a BIG tax handout for billionaires, paid for by ripping health insurance from 14 MILLION people. We must stop this from passing the Senate. <a href="https://t.co/JxHN0yWpMT">pic.twitter.com/JxHN0yWpMT</a>
&mdash; Elizabeth Warren (@SenWarren) <a href="https://twitter.com/SenWarren/status/1925590808167677993?ref_src=twsrc%5Etfw">May 22, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: The Massachusetts senator specifically targeted tech moguls who attended Trump&#8217;s inauguration, claiming they &#8220;paid millions of dollars to stand in the front row&#8221; and are now &#8220;popping bottles of champagne that cost more than your rent.&#8221;
Market analysts acknowledge short-term economic benefits but express concern over long-term fiscal consequences. Jed Ellerbroek of Argent Capital Management told CNBC the package &#8220;will boost the economy in the short term&#8221; through tax cuts and increased defense spending, but warned it will <a href="https://www.benzinga.com/news/25/05/45581297/trumps-big-beautiful-3-8-trillion-bill-squeaks-through-house-expert-says-it-will-boost-the-economy-in-the-short-term-but-worsen-deficits">burden America with higher deficits</a>.
The Congressional Budget Office estimates the legislation could increase national debt by $2.3 trillion to $5.7 trillion by 2034, adding to the current <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45564489/trumps-big-tax-bill-clears-the-house-30-year-yields-jump-to-515-as-bond-market-freaks">record $36.2 trillion federal debt</a>. The bill also eliminates key federal retirement benefits, including the FERS supplement for <a href="https://www.benzinga.com/25/05/45580298/trumps-big-beautiful-bill-strips-key-retirement-benefits-from-federal-workers-in-razor-thin-house-vote">workers retiring before age 62</a>.
Warren urged Senate Democrats to &#8220;stop this thing from passing the Senate.&#8221;
Image Via Shutterstock 
Read Also:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/25/05/45580812/trump-may-want-a-recession-market-observers-say-it-serves-his-economic-agendalower-rates-inflation-and-trade-deficit">Trump May &#8216;Want&#8217; A Recession: Market Observer Says It Serves His Economic Agenda—Lower Rates, Oil Prices, And Trade Deficit</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.

Health Care

Politics

Economics

ENPH

FSLR

Elizabeth Warren Says Jeff Bezos And Elon Musk 'Are Popping Champagne' As House Passes Trump's 'Big, Beautiful Bill' She Calls A Handout To Billionaires

WIIM

ALHC

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Shares of health insurance stocks are trading lower after CMS announced a strategy to enhance and accelerate Medicare Advantage audits.

The House Rules Committee advanced President Donald Trump&#8217;s &#8220;One Big Beautiful Bill Act&#8221; in an 8-4 vote following a marathon 22-hour hearing, setting up a potential overnight floor vote as Republicans push forward with the $4.9 trillion legislative package despite internal GOP divisions.
What Happened: House Republicans made key concessions to appease conservative and moderate holdouts before advancing the megabill, as <a href="https://abcnews.go.com/Politics/committee-advances-trump-megabill-full-house-after-aimed/story?id=122059925">reported</a> by ABC News.
The committee approved accelerated Medicaid work requirements starting December 31, 2026, instead of 2029, while raising the state and local tax (SALT) deduction cap to $40,000 for incomes under $500,000, up from the current $10,000 limit established in the 2017 Tax Cuts and Jobs Act.
The revised bill also expedites cuts to Biden-era clean energy tax credits, requiring new projects to break ground within 60 days or be &#8220;placed in service&#8221; by end-2028.
Additionally, the Department of Homeland Security receives $12 billion through September 2029 for border security reimbursements to states.
Texas Rep. Chip Roy was notably absent from the committee vote, while Democrats employed stalling tactics on the House floor to slow the bill&#8217;s progress. The changes came after Trump met Wednesday with House Speaker Mike Johnson and Freedom Caucus members following failed Tuesday negotiations, with White House press secretary Karoline Leavitt calling the meeting &#8220;productive.&#8221;
See Also: <a href="https://www.benzinga.com/25/05/45557725/as-microsoft-faces-internal-protests-over-israel-ties-workers-say-emails-with-palestine-and-gaza-are-getting-censored-companywide-report">Microsoft Faces Employee Protests Over Email Censorship, Satya Nadella-Led Company Explains Rationale</a>
Why It Matters: The bill&#8217;s passage would significantly <a href="https://www.benzinga.com/government/regulations/25/05/45506863/trumps-big-beautiful-bill-advances-heres-who-wins-and-loses">impact multiple sectors</a>. Defense contractors including RTX Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>), Lockheed Martin Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>), Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>), and Booz Allen Hamilton Holding Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>) could benefit from increased military spending provisions.
Conversely, Medicaid managed care organizations face enrollment volatility risks, potentially affecting UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), Centene Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>), and Elevance Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>).
Clean energy stocks, including First Solar Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>), Enphase Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>), and Sunrun Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>), dropped on Monday as investors weighed reduced tax credit impacts.
The Congressional Budget Office (CBO) projects the legislation would increase the <a href="https://www.benzinga.com/markets/equities/25/05/45536595/big-beautiful-bill-will-explode-the-deficit-and-make-the-rich-richer-congressional-budget-office-estimates-4-income-fall-for-lowest-decile-of-americans-by-2033">federal deficit by $3.8 trillion</a> while reducing Medicaid subsidies by $698 billion and SNAP spending by $267 billion.
The CBO analysis shows that the lowest income decile would lose approximately 2% of household resources in 2027 and 4% by 2033, while the highest decile gains 4% in 2027.
Senate Republicans have already signaled plans for additional changes, creating uncertainty for the final passage of Trump&#8217;s signature legislative priority.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45557591/nayib-bukele-hits-back-at-naysayers-after-bitcoin-bolts-past-110000-they-said-dont-take-screenshots-take-profits-flaunts-el-salvadors-neat-gains">Nayib Bukele Hits Back At Naysayers After Bitcoin Bolts Past $110,000: &#8216;They Said, Don&#8217;t Take Screenshots, Take Profits&#8217; — Flaunts El Salvador&#8217;s Neat Gains</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Equities

PLTR

House Advances Trump's 'One Big Beautiful Bill' After Key Medicaid, Tax, And Border Security Changes

<h2>CMS Rolls Out Aggressive Strategy to Enhance and Accelerate Medicare Advantage Audits</h2>

Biotech

'CMS Rolls Out Aggressive Strategy To Enhance And Accelerate Medicare Advantage Audits; Agency Will Begin Auditing All Eligible Medicare Advantage Contracts Each Payment Year And Add Resources To Expedite Completion Of 2018 To 2024 Audits'

Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) has outperformed the market over the past 20 years by 2.34% on an annualized basis producing an average annual return of 10.65%. Currently, Centene has a market capitalization of $30.97 billion. 
Buying $1000 In CNC: If an investor had bought $1000 of CNC stock 20 years ago, it would be worth $7,575.55 today based on a price of $62.23 for CNC at the time of writing.
<h3>Centene's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747753218_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 20 Years Ago, You Would Have This Much Today

President Donald Trump's sweeping legislative package is, as expected, divisive. Republicans are pitching it as &#8220;One, Big Beautiful Bill.&#8221; Democrats are <a href="https://www.youtube.com/watch?v=D2cwPUb21IE">calling it</a> &#8220;one big beautiful betrayal.&#8221; Here's a look at some of the bill&#8217;s <a href="https://www.benzinga.com/personal-finance/25/05/45485150/the-one-big-beautiful-bill-would-create-maga-savings-accounts-with-a-1000-gift-from-the-government-at-birth">key elements</a>.&nbsp;
The Winners: The bill seeks to extend The Tax Cuts and Jobs Act (TCJA) of 2017. That means the expiring provisions that benefit high-income and wealthy earners would be permanent.
It also seeks to eliminate federal taxes on tips and overtime pay, fulfilling some of Trump&#8217;s campaign promises.&nbsp;
The tax breaks would reduce revenue by $4.9 trillion over the decade, but increase spending on military, defense and border security. 
So, if legislators sign the bill into law, major U.S. defense contractors like RTX Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) and Lockheed Martin Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) could benefit from increased defense spending.&nbsp;
Other companies exposed to the defense sector including Palantir Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) and Booz Allen Hamilton Holding Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>) could also benefit from increased military and defense spending.&nbsp;
Read Next: <a href="https://www.benzinga.com/news/large-cap/25/05/45499101/big-short-legend-michael-burry-bets-big-on-lipstick-index-is-he-bracing-for-a-recession?utm_source=article">&#8216;Big Short&#8217; Legend Michael Burry Bets Big On Lipstick Index: Is He Bracing For A Recession?</a>
The Losers: The cost of the tax bill will be partially balanced with new taxes on private university endowments and significant cuts to programs like Medicaid.
Stocks of major Medicaid managed care organizations could be vulnerable to enrollment volatility and premium pricing challenges if the changes are approved. Investors would be wise to monitor UnitedHealth Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), Centene Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) and Elevance Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) as the bill moves through Congress. 
Low-income Americans who rely on food assistance should also take note. House Republicans are proposing major changes to the Supplemental Nutrition Assistance Program, or SNAP. The program aids over 42 million Americans. The bill would shift 5% of benefit costs and 75% of administrative costs to states, up from the current 50% share for administration only. It also seeks to expand work requirements to recipients up to age 64.
Democrats have criticized the move as harmful to families, while Republicans say it promotes work and cuts waste. The House Agriculture Committee has already <a href="https://www.politico.com/live-updates/2025/05/14/congress/house-agriculture-committee-approves-300-billion-in-nutrition-spending-cuts-00350900">approved</a> $300 million in SNAP cuts to help fund tax breaks.
If the<a href="https://www.benzinga.com/general/health-care/25/05/45431505/gop-tax-bill-breaks-trumps-social-security-tax-pledge-still-hits-25-million-seniors-while-elon-musks-stock-wealth-skirts-fica"> legislative package</a> is passed, it would also be the end of many clean energy initiatives and key tax credits and would impose new fees on electric vehicles. These changes could slow the growth of the clean energy sector and make electric vehicles and renewables less competitive compared to traditional energy sources.&nbsp;
Clean energy stocks including Enphase Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>), First Solar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) and Sunrun, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) were all sharply lower on Monday as investors digested the potential effects on the industry.&nbsp;
The 1,116-page bill also wouldn&#8217;t quell fears about America&#8217;s public debt, which currently stands at $36 trillion. According to the nonpartisan watchdog group, the Committee for a Responsible Federal Budget, the bill <a href="https://www.crfb.org/blogs/adding-house-reconciliation-bill">adds</a> approximately $3.3 trillion to the national debt over the next ten years.
What's Next: After advancing out of the House Budget Committee in a rare Sunday meeting by a narrow 17-16 vote, Trump&#8217;s &#8220;One Big, Beautiful Bill&#8221; faces several<a href="https://www.benzinga.com/25/05/45481745/donald-trump-backed-gop-bill-seeks-to-ban-states-from-regulating-ai-for-10-years-critics-warn-its-federal-overreach-that-could-backfire"> key steps</a> before it can become law.
The next stop is the House Rules Committee, which will meet midweek to set the terms for floor debate, consider possible amendments, and make any necessary last-minute adjustments to the bill before it heads to a full vote on the House floor. 
If the bill passes the House, it will move to the Senate where it may face additional challenges, as Republican senators are also seeking changes that could complicate final passage.
Further changes to the bill are possible as leaders work to secure enough support from both conservative and moderate factions.&nbsp;
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/health-care/25/05/45384935/trump-again-promises-lower-drug-prices-by-cutting-out-middlemen-like-unitedhealth-cvs-will-it-work-this-time?utm_source=articleShare">Trump Again Promises Lower Drug Prices By &#8216;Cutting Out Middlemen&#8217; Like UnitedHealth, CVS: Will It Work This Time?</a></li>
</ul>
Photo: Shutterstock&nbsp;

Government

Large Cap

Regulations

Movers

Tech

Trump's 'Big Beautiful Bill' Advances: Here's Who Wins And Loses

Centene's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) short percent of float has fallen 19.26% since its last report. The company recently reported that it has 8.57 million shares sold short, which is 1.97% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.57 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Centene Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747684836_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Centene has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Centene's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Centene's peer group average for short interest as a percentage of float is 4.72%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Do Investors Really Feel About Centene?

iShares Trust Dow Jones US Healthcare Sector Index Fund

Shares of health insurance stocks are trading lower after UnitedHealth suspended its 2025 outlook as medical expenditures were expected to be larger than anticipated.

Reported Friday, Arizona Complete Health Secures Six-Year Contract To Lead Arizona Long Term Care Medicaid Services

Jefferies analyst David Windley maintains Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) with a Hold and lowers the price target from $64 to $61.

Jefferies Maintains Hold on Centene, Lowers Price Target to $61

Guggenheim analyst Jason Cassorla reiterates Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) from Neutral to Neutral.

Reiteration

Guggenheim Reiterates Neutral on Centeneto Neutral

4 analysts have shared their evaluations of Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $72.25, a high estimate of $84.00, and a low estimate of $64.00. A decline of 1.37% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1745848869_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Centene. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Andrew Mok &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $84.00&#x7C;$93.00 &#x7C; 
&#x7C;Michael Ha &#x7C;Baird &#x7C;Lowers &#x7C;Neutral &#x7C; $69.00&#x7C;$71.00 &#x7C; 
&#x7C;David Windley &#x7C;Jefferies &#x7C;Raises &#x7C;Hold &#x7C; $64.00&#x7C;$53.00 &#x7C; 
&#x7C;Stephen Baxter &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $72.00&#x7C;$76.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Centene. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Centene compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Centene's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Centene's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CNC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Centene analyst ratings.</a>
<h2>Get to Know Centene Better</h2>
Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of December 2024, mostly in Medicaid (about 60% of membership), the individual exchanges (about 20%), and Medicare (about 5%). The company also has a military contract and provides Medicare Part D pharmaceutical plans.
<h3>Centene's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Centene's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 3.41%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 0.69%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Centene's ROE excels beyond industry benchmarks, reaching 1.05%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Centene's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.34%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.74, Centene adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 4 Analyst Projections For Centene

Barclays analyst Andrew Mok maintains Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) with a Overweight and lowers the price target from $93 to $84.

Barclays Maintains Overweight on Centene, Lowers Price Target to $84

Wall Street's three-day rally came to a pause on Friday, with major indices hovering near the flatline by midday in New York as caution returned amid mixed signals on <a href="https://www.benzinga.com/news/global/25/04/45004954/china-reportedly-begins-exempting-key-us-imports-from-tariffs-including-pharma-and-aerospace-parts">U.S.-China trade relations.</a>
President Donald Trump claimed to have held a phone call with President Xi Jinping, yet Chinese officials denied that any talks had taken place.
Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) extended its rally into a fourth consecutive session, notching its best weekly performance of the year with a 16% gain. On Thursday afternoon, Transportation Secretary Sean Duffy introduced a new regulatory framework for self-driving vehicles, saying it aimed to reduce bureaucratic hurdles and advance toward a unified national standard.
T-Mobile US Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NYSE">TMUS</a>) was the biggest laggard of the day, falling 11%, on track for its worst single-day loss since March 2020. This came despite better-than-expected earnings, as its core wireless business posted slower growth than analysts had projected.
Among sectors, consumer discretionary led gains, buoyed by Tesla's 8% gain, while materials underperformed.
In fixed income, Treasury yields declined for a fourth straight session, underscoring how critical Trump's early-week reassurance — that he would not dismiss Fed Chair Jerome Powell — was for bond market sentiment.
The yield on the 10-year Treasury note dropped 4 basis points to 4.27%, on course for its lowest close since April 8.
In commodities, gold slid 2%, oil held steady at $62 per barrel, and natural gas rose 1% to $3 per million British thermal units, snapping a 10-session losing streak.
In crypto markets, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) rose 1.2% to $95,000.
<h2 class="wp-block-heading">Friday&#8217;s Performance In Major US Indices, ETFs</h2>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>Chg</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>19,250.90</td>
<td>+0.2%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,488.71</td>
<td>+0.1%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>39,908.60</td>
<td>-0.5%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1,942.82</td>
<td colspan="2">-0.8%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 12 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) flattened at $546.92.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) eased 0.5% to $399.23.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;fell 0.2% to $468.61.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) fell 0.7% to $192.79.</li>
<li>The&nbsp;Consumer Discretionary&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) outperformed, up 1.1%; the&nbsp;Materials Care&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>) lagged, down 1.1%.</li>
</ul>
<h3 class="wp-block-heading">Friday&#8217;s Stock Movers</h3>
Stocks reacting to earnings report included:
<ul>
<li>Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>): up 1.7%</li>
<li>T-Mobile US Inc.: down 10.9%</li>
<li>AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>): up 2.4%</li>
<li>Intel Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>): down 7.2%</li>
<li>Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>): down 3.2%</li>
<li>Aon plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>): down 11.0%</li>
<li>Republic Services Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSG#NYSE">RSG</a>): down 0.2%</li>
<li>Digital Realty Trust Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLR#NYSE">DLR</a>): up 3.0%</li>
<li>HCA Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>): down 5.2%</li>
<li>Charter Communications Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>): up 10.3%</li>
<li>The Hartford Financial Services Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIG#NYSE">HIG</a>): down 1.1%</li>
<li>Weyerhaeuser Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WY#NYSE">WY</a>): down 2.1%</li>
<li>Colgate-Palmolive Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>): up 1.1%</li>
<li>Centene Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>): down 7.7%</li>
<li>LyondellBasell Industries N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYB#NYSE">LYB</a>): up 0.0%</li>
<li>VeriSign Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSN#NASDAQ">VRSN</a>): up 9.1%</li>
<li>Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>): down 2.0%</li>
<li>Carrier Global Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARR#NYSE">CARR</a>): down 0.5%</li>
<li>Schlumberger Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>): down 0.7%</li>
<li>Erie Indemnity Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERIE#NASDAQ">ERIE</a>): down 11.8%</li>
<li>Principal Financial Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFG#NASDAQ">PFG</a>): down 1.4%</li>
<li>Eastman Chemical Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>): down 6.0%</li>
<li>Healthpeak Properties Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>): down 4.7%</li>
</ul>
Read now: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45009066/goldman-sachs-upgrades-charles-schwab-to-buy-one-of-the-best-earnings-growth-outlooks-analyst-says">Goldman Sachs Upgrades Charles Schwab To Buy: &#8216;One Of The Best Earnings Growth Outlooks,&#8217; Analyst Says</a></li>
</ul>
Photo: Shutterstock

Macro Economic Events

Broad U.S. Equity ETFs

Econ #s

ETFs

$BTC

ABBV

CARR

CHTR

SPDR Dow Jones Industrial Average ETF Trust

ERIE

GILD

GOOGL

INTC

TMUS

TSLA

VRSN

Select Sector SPDR-Consumer Discretionary

Wall Street Rally Pauses, Tesla Heads For Strongest Week In 6 Months: What's Driving Markets Friday?

Earnings

Press Releases

CENTENE CORPORATION REPORTS FIRST QUARTER 2025 RESULTS

Oklahoma Complete Health Offers New and Upgraded Benefits for SoonerSelect Members in 2025

Contracts

CENTENE SUBSIDIARY ARIZONA COMPLETE HEALTH JOINS SETTLEMENT AGREEMENT TO MOVE FORWARD WITH STATEWIDE LONG-TERM CARE MEDICAID CONTRACT

NVA Appoints Ken Burdick Executive Chairman Ahead of Future IPO

Delaware First Health and the Centene Foundation Announce Grant Program Open Submission Period

Meridian Health Plan of Illinois Partners with Farmers Markets to Combat Food Insecurity

Superior HealthPlan Awards $200,000 in Grants to 20 Community-Based Organizations and Providers

Health Net and Centene Foundation Invest More than $7.2 Million to Increase Patient Access to Care with Expanded Fleet of Mobile Clinics in California

Justice-Involved Individuals Reentering Society in Sacramento County Find a Place to Call Home Through a $2.6M Grant from Health Net to 'Break the Cycle'

Comments

Centene

Intérêt court

Centene (NYSE:CNC) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL